Head and Neck Squamous Cell Carcinoma
Conditions
Brief summary
This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.
Interventions
Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
DRUGcisplatin
Cisplatin :75mg/m2, D1, IV(21 days/cycle)
albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
Sponsors
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients voluntarily joined the study, signed the informed consent, and had good compliance; * Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-1; * Patients with untreated head and neck squamous cell carcinoma who were pathologically confirmed and determined to be suitable for surgical treatment were classified as stage III, IVa according to AJCC (8th Edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers * Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.
Exclusion criteria
* Patients who have previously used PD-1/PD-L1/CTLA-4 antibody therapy; * Patients who require systemic treatment with corticosteroids (\> 10mg daily prednisone equivalent) or other immunosuppressive drugs within 14 days prior to administration or during treatmentIn the absence of active autoimmune disease, inhaled or topical steroids and adrenocortical hormone at doses \>10mg/ day equivalent to prednisone and adrenocortical hormone replacement at therapeutic doses not exceeding 10mg/ day prednisone are permitted; * A history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; * Active or uncontrolled severe infection within 4 weeks prior to enrollment (CTCAE grade 2 infection); * Abnormal function of major organs * Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major pathological response（MPR） | One year | Major pathologic response is based on the pathological examination on the post-operative specimens. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse event rate | Baseline up to 3 years. | The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
| Disease-free survival at 2 years(DFS at 2 years) | Baseline up to 2 years. | The proportion of subjects disease-free survival at 2 years |
| Overall Response Rate (ORR) | Baseline up to 3 years. | The proportion of subjects who achieves a best overall response of CR or PR. |
| Disease-control Rate（DCR） | Baseline up to 3 years. | The proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks). |
| distant metastasis-free survival at 2 years(DMFS at 2 years) | Baseline up to 2 years. | The proportion of subjects distant metastasis-free survival at 2years |
| OS at 2 years | Baseline up to 2 years. | The overall survival time refers to the time from initiating inductive therapy to death due to any cause. |
| pathologic complete response(pCR) | One year | Pathological examination showed the presence of 0% active tumor in the tissue specimen |
| Local recurrence-free survival at 2years(LRFS at 2 years) | Baseline up to 2 years. | The proportion of subjects local recurrence-free survival at 2years |
Countries
China
Contacts
Primary ContactMin Ruan, PhD
Outcome results
None listed